Blenrep (belantamab mafodotin)
Relapsed/Refractory Multiple Myeloma
Key Facts
About GSK
GSK is a fully focused, global biopharma leader with a market cap exceeding $112B, formed in 2000 and sharpened by the 2022 demerger of its consumer health business. The company leverages deep expertise in vaccines, immunology, and genetics to build a robust pipeline across its four core therapeutic areas. Its strategy is centered on disciplined R&D investment in high-value modalities, including long-acting therapies and next-generation oncology agents, to drive sustainable growth and significant public health impact.
View full company profileAbout GSK plc
GSK is a London-headquartered, publicly traded biopharma giant with a market cap of ~$109B, focused exclusively on pharmaceuticals and vaccines following the 2022 spin-off of its consumer health division. Its mission is to positively impact the health of 2.5 billion people by 2030 through disciplined R&D in four core therapeutic areas: Respiratory/Immunology, Oncology, HIV, and Infectious Diseases. The company leverages advanced genetic research, AI, and platform technologies to drive a pipeline of approximately 130 programs, aiming for sustained growth from both its established portfolio and novel pipeline assets.
View full company profileTherapeutic Areas
Other Relapsed/Refractory Multiple Myeloma Drugs
| Drug | Company | Phase |
|---|---|---|
| Aplidin (plitidepsin) | PharmaMar | Approved (Conditional - AU) |
| TECVAYLI + DARZALEX FASPRO | johnson-and-johnson-innovative-medicine | Approved |
| Linvoseltamab | Regeneron | Phase 3 |
| CAR T-Cell Therapy Program | Dr. Reddy's Laboratories | Development |
| HDP-101 | Heidelberg Pharma | Phase I/IIa |
| inobrodib + Pd (InoPd) | CellCentric | Phase 1/2 |
| CT053 | CARsgen Therapeutics | Phase Ib/II |
| CT059 | CARsgen Therapeutics | Phase I |
| P-BCMA-ALLO1 | Poseida Therapeutics | Phase 1 |
| P-BCMA-101 | Poseida Therapeutics | Phase 1/2 |
| ABBV-383 | AbbVie | Phase 1 |
| bri-cel (BAY 2413334) | Bayer | Phase I |